Savient Pharmaceuticals Inc Com (NASDAQOTH:SVNTQ)

CAPS Rating: 2 out of 5

A biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets.


Player Avatar darthballs (47.44) Submitted: 10/27/2010 11:11:32 AM : Outperform Start Price: $11.62 SVNTQ Score: -156.68

Slammed almost 50% because it couldn't find a buyer at it's already run-up speculated price. Remember it still has a fresh FDA approval of Krystexxa for arthritis, so the risk/reward at this point is very appealing.Potential for a quick pop from another (albeit lower) buyout price, or it can ride the Krystexxa sales for a while.

Featured Broker Partners